GRAIL shares are trading lower. The company announced that the first participant has been enrolled in the REACH/Galleri-Medicare study at Community Health Network.

7/18/24 11:52:27 AM ET

Medical Specialities

Health Care

Get the next $GRAL alert in real time by email

Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri® in Addition to Currently Recommended Cancer Screenings

Study Enrollment Includes Focus on Diverse and Underrepresented Populations

Costs of Galleri and Related Items and Services for Study Participants Will be Covered by Medicare

Get the next $GRAL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$GRAL

Date	Price Target	Rating	Analyst
11/15/2024		Peer Perform	Wolfe Research
10/17/2024		Neutral	Guggenheim

More analyst ratings

GRAIL Reports Third Quarter 2024 Financial Results
Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif., Nov. 12, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024. Revenue in the third quarter was $28.7 million, representing 38% growth year over year, and revenue for Galleri was $25.4 million, representing 52% growth year over year. Ne
11/12/24 4:06:00 PM ET
$GRAL
Medical Specialities
Health Care
GRAIL to Announce Third Quarter 2024 Financial Results
MENLO PARK, Calif., Oct. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2024 following the close of market on Tuesday, Nov. 12, 2024. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Third Quarter 2024 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inves
10/29/24 4:01:00 PM ET
$GRAL
Medical Specialities
Health Care
GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update
Second Quarter Revenue Grew 43% Year-Over-Year to $32.0 Million Portfolio Prioritization and Corporate Restructure Extends Cash Runway into 2028 MENLO PARK, Calif., Aug. 13, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2024. Revenue in the second quarter was $32.0 million, representing 43% growth year over year. Net loss for the quarter, which includes amortization and impairment of acquisition-related intangible items, was
8/13/24 4:01:00 PM ET
$GRAL
Medical Specialities
Health Care

$GRAL
Press Releases

Fastest customizable press release news feed in the world

GRAIL to Participate in Upcoming Investor Conferences
MENLO PARK, Calif., Nov. 19, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences. Piper Sandler 36th Annual Healthcare Conference in New York, NY: fireside chat on Tuesday, Dec. 3 at 1:30 p.m. ET7th Annual Evercore ISI HealthCONx Conference in Coral Gables, Fla.: fireside chat on Wednesday, Dec. 4 at 3:50 p.m. ETLive and replay webcasts may be accessed in the investor relations section of GRAIL's website a
11/19/24 4:05:00 PM ET
$GRAL
Medical Specialities
Health Care
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
MENLO PARK, Calif., Nov. 18, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca (NASDAQ:AZN) in collaboration with Daiichi Sankyo (TSE: 4568). The study, which is being conducted under a
11/18/24 4:01:00 PM ET
$AZN
$GRAL
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
GRAIL Reports Third Quarter 2024 Financial Results
Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif., Nov. 12, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024. Revenue in the third quarter was $28.7 million, representing 38% growth year over year, and revenue for Galleri was $25.4 million, representing 52% growth year over year. Ne
11/12/24 4:06:00 PM ET
$GRAL
Medical Specialities
Health Care

$GRAL
Market Insights

Live Market Insights

GRAIL shares are trading lower. The company announced that the first participant has been enrolled in the REACH/Galleri-Medicare study at Community Health Network.
Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri® in Addition to Currently Recommended Cancer ScreeningsStudy Enrollment Includes Focus on Diverse and Underrepresented PopulationsCosts of Galleri and Related Items and Services for Study Participants Will be Covered by Medicare
7/18/24 11:52:27 AM ET
$GRAL
Medical Specialities
Health Care
GRAIL Announces First Participant Enrolled In REACH Study Evaluating Clinical Impact Of Galleri Multi-Cancer Early Detection Test In The Medicare Population
Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri® in Addition to Currently Recommended Cancer ScreeningsStudy Enrollment Includes Focus on Diverse and Underrepresented PopulationsCosts of Galleri and Related Items and Services for Study Participants Will be Covered by MedicareMENLO PARK, Calif., July 18, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first participant has been enrolled in the REACH/Galleri-Medicare study at Community Health Network, a leading integrated healthcare system in central
7/18/24 9:08:34 AM ET
$GRAL
Medical Specialities
Health Care
Dow Rallies To All-Time Highs, Small Caps Outperform Tech, Gold Hits Records On Heightened September Rate Cut Bets: What's Driving Markets Tuesday?
Wall Street continues to experience a series of memorable days, with the bulls riding the rally with increasing confidence, certain that the Federal Reserve will begin cutting interest rates in September. Fed futures currently indicate a 100% probability that policymakers will cut interest rates in two months, according to the CME Group‘s FedWatch tool. This time, blue-chip stocks and gold are stealing the spotlight by breaking their all-time highs, while small caps, as tracked by the iShares Russell 2000 ETF (NYSE:IWM), have posted their fifth consecutive day in the green, marking their best five-day rally in over four years. The Dow Jones Industrial Average surged to 40,800 points
7/16/24 1:20:15 PM ET
$BA
$BAC
$DJT
$GRAL
Aerospace
Industrials
Major Banks
Finance

GRAIL shares are trading lower. The company announced that the first participant has been enrolled in the REACH/Galleri-Medicare study at Community Health Network.

Chat with this insight

Recent Analyst Ratings for $GRAL

$GRAL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Freidin Aaron sold $426,937 worth of shares (30,452 units at $14.02), decreasing direct ownership by 10% to 268,277 units (SEC Form 4)

SEC Form 4 filed by President Ofman Joshua J.

Director Krevans Sarah was granted 31,055 shares (SEC Form 4)

$GRAL Financials

Live finance-specific insights

GRAIL Reports Third Quarter 2024 Financial Results

GRAIL to Announce Third Quarter 2024 Financial Results

GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update

$GRAL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

$GRAL Press Releases

Fastest customizable press release news feed in the world

GRAIL to Participate in Upcoming Investor Conferences

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

GRAIL Reports Third Quarter 2024 Financial Results

$GRAL SEC Filings

SEC Form 10-Q filed by GRAIL Inc.

GRAIL Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

GRAIL Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

$GRAL Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by GRAIL Inc.

SEC Form SC 13G filed by GRAIL Inc.

Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

$GRAL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wolfe Research initiated coverage on GRAIL

Guggenheim initiated coverage on GRAIL

$GRAL Market Insights

Live Market Insights

GRAIL shares are trading lower. The company announced that the first participant has been enrolled in the REACH/Galleri-Medicare study at Community Health Network.

GRAIL Announces First Participant Enrolled In REACH Study Evaluating Clinical Impact Of Galleri Multi-Cancer Early Detection Test In The Medicare Population

Dow Rallies To All-Time Highs, Small Caps Outperform Tech, Gold Hits Records On Heightened September Rate Cut Bets: What's Driving Markets Tuesday?

$GRAL Leadership Updates

Live Leadership Updates

GRAIL Appoints Sarah Krevans to Board of Directors

Wheels Up Announces Gregory Summe to Join Board of Directors

Recent Analyst Ratings for
$GRAL

$GRAL
Insider Trading

$GRAL
Financials

$GRAL
Insider Purchases

$GRAL
Press Releases

$GRAL
SEC Filings

$GRAL
Large Ownership Changes

$GRAL
Analyst Ratings

$GRAL
Market Insights

$GRAL
Leadership Updates